ClinicalTrials.gg
CompletedNCT06738485Updated Oct 23, 2026

Recombinant Single-chain Factor VIII (rVIII-SingleChain) in Chinese Participants With Hemophilia A Previously Treated With FVIII Products

A Phase 3 interventional study of Recombinant single-chain factor VIII (rVIII-SingleChain) in Congenital Hemophilia A, sponsored by CSL Behring. Completed at 20 sites in China. Open to male participants aged 0 Days to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-23.

Sponsored by CSL Behring (part of CSL Limited) · Phase 3, Interventional, and Prevention

Updated Oct 23, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
62
Allocation
Not applicable
Ages
0 Days to 65 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies in Hemophilia A by CSL Limited — none open to participants now, none under way, none of them phase 3. Hemophilia A · CSL Limited.

Enrollment
6th of 11
62 · median 62
Started
2025
the only one that year
Phase 3
6 of 14
none open now
Registered
14th of 14
by date

Among the 14 studies in Hemophilia A by CSL Limited, this one is the 6th largest by enrollment of the 11 interventional ones that give a count, is the only one that started in 2025, is one of 6 in phase 3, and was the 14th registered.

Hemophilia A

844 studies on the registry are indexed under Hemophilia A; 136 are open to participants now.

Browse Hemophilia A studies →

Open to participants now

None of the 14 studies in Hemophilia A by CSL Limited is open now. The open studies under Hemophilia A, anywhere →

Who these studies take

Of the 87 Hemophilia A studies recruiting now, 51 (59%) set no upper age limit and 31 (36%) stop at 75 or younger; 55 take children under 18; 10 take healthy volunteers.

This study: 0 Days to 65 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 14 studies in Hemophilia A by CSL Limited as a file.
02

Study summary

For bridging the available global clinical data of rVIII-SingleChain, with the Chinese population, the aim of this study in China is to investigate the pharmacokinetics (PK) of rVIII-SingleChain after an initial and repeat dose and to assess efficacy and safety during 2 to 3 times weekly prophylaxis treatment with rVIII-SingleChain in male Chinese PTPs with severe hemophilia A (FVIII activity less than [\<] 1%).

03

Conditions studied

  • Congenital Hemophilia A

Browse trials for

04

Who can participate

Ages eligible
0 Days to 65 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

    • Male Chinese participants \<= 65 years of age.
    • Participants with severe hemophilia A (FVIII activity \< 1%).
    • Participants who have received FVIII products for >= 150 EDs (>= 6 years of age) or >= 50 EDs (\< 6 years of age).

Exclusion criteria

Exclusion Criteria:

    • Known (allergic reaction or anaphylaxis) to any FVIII product or hamster protein.
    • Known congenital or acquired coagulation disorder other than congenital FVIII deficiency.
    • Currently receiving intravenous (IV) immunomodulating agents such as immunoglobulin or chronic systemic treatment.
    • Receiving any cryoprecipitate, whole blood, or plasma within 30 days before administration of rVIII-SingleChain.
    • Use of traditional or herbal Chinese medicine(s) with an impact on hemophilia, including coagulation, within 28 days before Day 1 and / or refusal to abstain from these during the study until the end of the participant's participation in the study.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
62 participants (actual)

Study arms

  • Experimental
    rVIII-SingleChain

    Participants will receive rVIII-SingleChain as an intravenous (IV) infusion for a minimum of 50 exposure days (EDs).

    Biological: Recombinant single-chain factor VIII (rVIII-SingleChain)

Interventions

06

What researchers measure

Primary outcomes

  1. Incremental Recovery (IR) of rVIII-SingleChain

    Time frame: Before, and at 30 minutes after the end of, rVIII-SingleChain administration on Day 1

  2. Maximum Concentration (Cmax) of rVIII-SingleChain

    Time frame: Before, and up to 72 hours (participants ≥ 12 years ) and 48 hours (participants < 12 years) after rVIII-SingleChain administration on Day 1

  3. Area Under the Plasma Concentration Time Curve from Time Zero to the Last Measurable Concentration (AUC0-last) of rVIII-SingleChain

    Time frame: Before, and up to 72 hours (participants ≥ 12 years ) and 48 hours (participants < 12 years) after rVIII-SingleChain administration on Day 1

  4. Area Under the Plasma Concentration Time Curve from Time Zero to Infinity (AUC0-inf) of rVIII-SingleChain

    Time frame: Before, and up to 72 hours (participants ≥ 12 years ) and 48 hours (participants < 12 years) after rVIII-SingleChain administration on Day 1

  5. Half-life (t1/2) of rVIII-SingleChain

    Time frame: Before, and up to 72 hours (participants ≥ 12 years ) and 48 hours (participants < 12 years) after rVIII-SingleChain administration on Day 1

  6. Clearance (Cl) of rVIII-SingleChain

    Time frame: Before, and up to 72 hours (participants ≥ 12 years ) and 48 hours (participants < 12 years) after rVIII-SingleChain administration on Day 1

  7. Annualized Spontaneous Bleeding Rate (AsBR)

    AsBR for treated bleeding episodes

    Time frame: Up to 29 weeks after rVIII-SingleChain administration

  8. Number of participants who develop FVIII inhibitors

    Time frame: During routine rVIII-SingleChain prophylaxis dosing, up to 29 weeks after rVIII-SingleChain administration.

Secondary outcomes

  1. Time to reach maximum concentration (Tmax) of rVIII-SingleChain

    Time frame: Before, and up to 72 hours (participants ≥ 12 years ) and 48 hours (participants < 12 years) after rVIII-SingleChain administration on Day 1

  2. Last Concentration (Clast) of rVIII-SingleChain

    Last observed quantifiable plasma concentration

    Time frame: Before, and up to 72 hours (participants ≥ 12 years ) and 48 hours (participants < 12 years) after rVIII-SingleChain administration on Day 1

  3. IR (participants ≥ 12 years of age) of rVIII-SingleChain (Repeat pharmacokinetic [PK])

    Time frame: Before, and at up to 72 hours after the end of, rVIII-SingleChain infusion at Week 28

  4. Cmax (participants ≥ 12 years of age) of rVIII-SingleChain (Repeat PK)

    Time frame: Before, and at up to 72 hours after the end of, rVIII-SingleChain infusion at Week 28

  5. AUC0-last of rVIII-SingleChain (Repeat PK)

    Time frame: Before, and at up to 72 hours after the end of, rVIII-SingleChain infusion at Week 28

  6. AUC0-inf of rVIII-SingleChain (Repeat PK)

    Time frame: Before, and at up to 72 hours after the end of, rVIII-SingleChain infusion at Week 28

  7. t1/2 of rVIII-SingleChain (participants ≥ 12 years of age) (Repeat PK)

    Time frame: Before, and at up to 72 hours after the end of, rVIII-SingleChain infusion at Week 28

  8. Cl of rVIII-SingleChain (participants ≥ 12 years of age) (Repeat PK)

    Time frame: Before, and at up to 72 hours after the end of, rVIII-SingleChain infusion at Week 28

  9. Annualized Bleeding Rate (ABR)

    Total ABR for treated, untreated, and both treated and untreated bleeding episodes (spontaneous, traumatic, and unknown cause)

    Time frame: Up to 29 weeks after rVIII-SingleChain administration

  10. Hemostatic Efficacy for Major and Nonmajor Bleeding Episodes

    The investigator will rate the efficacy of the rVIII-SingleChain treatment for major and nonmajor bleeding episodes based on a hemostatic efficacy four point rating scale of "excellent, good, moderate or no efficacy".

    Time frame: Up to 29 weeks after rVIII-SingleChain administration

  11. Consumption of rVIII-SingleChain - number of infusions (doses)

    Time frame: Up to 29 weeks after rVIII-SingleChain administration

  12. Consumption of rVIII-SingleChain - IU/kg per participant per month

    rVIII-SingleChain consumption (IU/kg) per participant per month, for the weekly regimen, on-demand treatment, and total treatment.

    Time frame: Up to 29 weeks after rVIII-SingleChain administration

  13. Consumption of rVIII-SingleChain - IU/kg per participant per year

    rVIII-SingleChain consumption (IU/kg) per participant per year, for the weekly regimen, on-demand treatment, and total treatment.

    Time frame: Up to 29 weeks after rVIII-SingleChain administration

  14. Number of bleeding episodes requiring rVIII-SingleChain to achieve hemostasis

    Number of bleeding episodes requiring 1, \<= 2, or \> 2 infusions (doses) of rVIII-SingleChain to achieve hemostasis

    Time frame: Up to 29 weeks after rVIII-SingleChain administration

  15. Percentage of bleeding episodes requiring rVIII-SingleChain to achieve hemostasis

    Percentage of bleeding episodes requiring 1, \<= 2, or \> 2 infusions (doses) of rVIII-SingleChain to achieve hemostasis

    Time frame: Up to 29 weeks after rVIII-SingleChain administration

  16. Number of participants who develop noninhibitory antibodies against rVIII-SingleChain

    Time frame: Before, and up to 29 weeks after, rVIII-SingleChain administration

  17. Number of participants who develop antibodies against Chinese hamster ovary host cell protein

    Time frame: Before, and up to 29 weeks after, rVIII-SingleChain administration

  18. Number of participants with Treatment-emergent Adverse Events (TEAEs), including related TEAEs, and serious adverse events (SAEs)

    Time frame: Up to 33 weeks after rVIII-SingleChain administration

  19. Percentage of participants with TEAEs, including related TEAEs, and serious adverse events (SAEs)

    Time frame: Up to 33 weeks after rVIII-SingleChain administration

  20. Number of TEAEs (events)

    Time frame: Up to 33 weeks after rVIII-SingleChain administration

07

Study locations

20 sites
  • The Second Hospital of Anhui Medical University
    Hefei, Anhui 230000, China
  • Beijing Children's Hospital
    Beijing, Beijing Municipality 100045, China
  • Children's Hospital of Chongqing Medical University
    Chongqing, Chongqing Municipality 400014, China
  • Fujian Medical University Union Hospital
    Fuzhou, Fujian 350001, China
  • Guangzhou Women and Children's Medical Center
    Guangzhou, Guangdong 510623, China
  • Nanfang Hospital of Southern Medical University
    Guangzhou, Guangdong 515399, China
  • Liuzhou People's Hospital
    Liuzhou, Guangxi 545006, China
  • North China University of Science and Technology Affiliated Hospital
    Tangshan, Hebei 63000, China
  • Hospital of Hematology, Chinese Academy of Medical Sciences
    Tianjin, Hebei 300020, China
  • Henan children's hospital Zhengzhou children's Hospital
    Zhengzhou, Henan 450053, China
  • Hunan Provincial Children's Hospital
    Changsha, Hunan 410021, China
  • Nanjing Children's Hospital
    Nanjing, Jiangsu 210008, China
  • XuZhou Children's Hospital
    Xuzhou, Jiangsu 221006, China
  • Jiangxi Provincial People's Hospital
    Nanchang, Jiangxi 212028, China
  • Quinghai Provincial People's Hospital
    Xining, Qinghai 81000, China
  • Jinan Central Hospital
    Jinan, Shandong 250013, China
  • Qingdao Women and Children's Hospital
    Qingdao, Shandong 266071, China
  • Shanghai Jiaotong University School of Medicine, Ruijin Hospital
    Shanghai, Shanghai Municipality 200020, China
  • The second affiliated hospital of Kunming Medical University
    Kunming, Yunan 650011, China
  • The Children's Hospital Zhejiang University School of Medicine
    Hangzhou, Zhejiang 310005, China
08

References and documents

Individual participant data

Plan to share: Yes — CSL will consider on a case-by-case basis requests to share Individual Patient Data (IPD) with external bona-fide, qualified scientific and medical researchers. For information on the process and requirements for submitting a voluntary data sharing request for IPD, please contact CSL at clinicaltrials@cslbehring.com.

Supporting information: Study protocol, Statistical analysis plan

Time frame: Requests for IPD will generally be considered once review by major regulatory authorities (i.e., FDA, EMA) is complete and the primary publication is available.

Access criteria: Proposed research should seek to answer a previously unanswered important medical or scientific question. Applicable country specific privacy and other laws and regulations will be considered and may prevent sharing of IPD. If the request is approved and the researcher has executed an appropriate data sharing agreement, IPD that has been appropriately anonymized will be available.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2025 to primary completion in Sep 2026, 20 months.

Of 89 industry-sponsored phase 3 interventional studies under Hemophilia A, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 56. This study's 20 months is below that.

Counting every sponsor, half of 91 studies reached it within 33 months; a quarter within 20 and three quarters within 56.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 23, 2026: primary completion Oct 2026 → Sep 2026 and completion Oct 2026 → Sep 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Dec 12, 2024
First posted
Dec 17, 2024
StartActual
Jan 9, 2025
Primary completionActual
Sep 23, 2026was Oct 2026
CompletionActual
Sep 23, 2026was Oct 2026
Last update
Oct 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Oct 23, 2026
Primary completion
Oct 26, 2026→Sep 23, 2026 (actual)
Oct 23, 2026
Study completion
Oct 26, 2026→Sep 23, 2026 (actual)
Oct 23, 2026
Enrollment
60 (estimated)→62 (actual)
Oct 23, 2026
Show all 1 update
  1. Oct 23, 2026
    Active, not recruiting→Completed
    Primary completion Oct 26, 2026→Sep 23, 2026 (now actual)
    Study completion Oct 26, 2026→Sep 23, 2026 (now actual)
    Enrollment 60 (estimated)→62 (actual)
    + 2 other changes: identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06738485
Lead sponsor
CSL Behring
Responsible party
Sponsor
First posted
Dec 17, 2024
Start date
Jan 9, 2025
Primary completion
Sep 23, 2026
Completion
Sep 23, 2026
Last update
Oct 23, 2026

Study contacts

Study Director
study director · CSL Behring

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lonoctocog alfa

Start the discussion